Tier 2 — strong

Efficacy and Optimal Dose of Coenzyme Q10 Supplementation on Inflammation-Related Biomarkers: A GRADE-Assessed Systematic Review and Updated Meta-Analysis of Randomized Controlled Trials

Shanshan Hou, Zezhong Tian, Dan Zhao, Ying Liang, Suming Dai, Qiuhua Ji, Zhiying Fan, Zhihao Liu, Meitong Liu, Yan Yang
Molecular Nutrition & Food Research 2023 67(13):e2200800

Bibliography

PubMed
PMID 37118903
DOI
10.1002/mnfr.202200800
Funding
Key Program of the National Natural Science Foundation of China (82030098); National Natural Science Foundation of China (81872617); Shenzhen Science, Technology and Innovation Commission (JCYJ20180307153228190); Chinese Nutrition Society Research Fund for DRIs.
Competing interests
The authors declared no conflict of interest.

Study snapshot

DesignSystematic review and meta-analysis of randomized controlled trials
ModelGRADE-assessed systematic review and updated meta-analysis restricted to double-blind randomized controlled trials evaluating CoQ10 and inflammatory biomarkers.
Sample31 double-blind RCTs; 1,517 participants.
InterventionCoQ10 supplementation versus placebo/control across double-blind RCTs; dose and duration varied. Dose-response/subgroup analyses explored whether effects differed across dose categories.
DurationVariable across included trials; literature searched through December 2022.
EndpointsC-reactive protein (CRP); Interleukin-6 (IL-6); Tumor necrosis factor-alpha (TNF-alpha); Circulating CoQ10; GRADE certainty; Dose-response/subgroup analyses; Risk of bias and sensitivity analyses

What the study showed, in plain terms

This 2023 GRADE-assessed meta-analysis included 31 double-blind randomized trials and 1,517 participants. It focused on three commonly studied circulating inflammatory markers—CRP, IL-6 and TNF-alpha—and also examined circulating CoQ10 exposure.

Pooled results favored CoQ10 for all three inflammatory markers: CRP SMD -0.40 (95% CI -0.67 to -0.13; p=0.003), IL-6 SMD -0.67 (95% CI -1.01 to -0.33; p<0.001), and TNF-alpha SMD -1.06 (95% CI -1.59 to -0.52; p<0.001). Circulating CoQ10 also increased, confirming biological exposure across studies.

The authors proposed that 300–400 mg/day showed the strongest inhibition of inflammatory markers in subgroup/dose analyses. That finding should not be converted into a universal dosing rule: it is derived from comparisons across heterogeneous trials, not a definitive randomized dose-ranging trial, and later umbrella evidence has shown substantial inconsistency among meta-analyses for some inflammatory outcomes.

Key findings

CRP: SMD -0.40, 95% CI -0.67 to -0.13, p=0.003.

IL-6: SMD -0.67, 95% CI -1.01 to -0.33, p<0.001.

TNF-alpha: SMD -1.06, 95% CI -1.59 to -0.52, p<0.001.

Biochemical exposure: circulating CoQ10 concentration increased with supplementation.

Dose analysis: authors proposed a stronger anti-inflammatory signal around 300–400 mg/day. This is subgroup/meta-analytic dose evidence rather than direct head-to-head randomized dose proof.

Eligibility was restricted to double-blind RCTs, strengthening internal validity relative to reviews that mixed open-label/nonblinded studies. Database searching extended through December 2022.

What this study can and cannot tell us

Inflammatory biomarker trials differed in population, baseline inflammation, dose, duration, formulation and comedications; pooled standardized effects therefore combine clinically heterogeneous contexts.

CRP, IL-6 and TNF-alpha are surrogate biomarkers. Changes do not establish reduced cardiovascular events, infection, disability or mortality.

The proposed 300–400 mg/day optimal range is generated from between-study subgroup/dose patterns and is vulnerable to ecological confounding.

The magnitude and even direction of pooled inflammatory effects differ across published meta-analyses/umbrella syntheses, particularly for TNF-alpha, so the evidence should be presented as heterogeneous rather than settled.

Publication-level GRADE assessment improves transparency but does not eliminate limitations of the underlying small trials.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology